{"id":"placebo-to-vgcv","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL6068498","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valganciclovir is rapidly converted to ganciclovir in the body, where it is phosphorylated by viral kinases and incorporated into viral DNA, causing chain termination and inhibition of CMV DNA synthesis. This mechanism is selective for CMV-infected cells because the virus expresses the kinase necessary for initial phosphorylation.","oneSentence":"VGCV (valganciclovir) is a prodrug of ganciclovir that inhibits viral DNA polymerase to suppress cytomegalovirus (CMV) replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:44.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cytomegalovirus (CMV) infection prophylaxis and treatment in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT03586284","phase":"PHASE2, PHASE3","title":"Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-03-15","conditions":"Cytomegalovirus Anterior Uveitis","enrollment":51},{"nctId":"NCT06334497","phase":"PHASE3","title":"Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-08-14","conditions":"Cytomegalovirus Infection","enrollment":80},{"nctId":"NCT04724447","phase":"PHASE1, PHASE2","title":"ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION","status":"RECRUITING","sponsor":"Laureate Institute for Brain Research, Inc.","startDate":"2021-11-23","conditions":"Major Depressive Disorder","enrollment":24},{"nctId":"NCT01649869","phase":"PHASE2","title":"Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02-24","conditions":"Cytomegalovirus Infection","enrollment":54},{"nctId":"NCT03443869","phase":"PHASE3","title":"Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-05-03","conditions":"CMV Disease","enrollment":601},{"nctId":"NCT02927067","phase":"PHASE3","title":"A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants","status":"COMPLETED","sponsor":"Shire","startDate":"2017-04-14","conditions":"Cytomegalovirus (CMV)","enrollment":553},{"nctId":"NCT00478465","phase":"PHASE1, PHASE2","title":"Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-05","conditions":"Chronic Fatigue Syndrome","enrollment":30},{"nctId":"NCT02871401","phase":"PHASE1","title":"A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-01-03","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":31},{"nctId":"NCT02439957","phase":"PHASE3","title":"A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-09","conditions":"Cytomegalovirus Disease, Kidney Transplant Infection","enrollment":6},{"nctId":"NCT00264290","phase":"PHASE4","title":"Valganciclovir to Reduce T Cell Activation in HIV Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2006-08","conditions":"HIV Infections, Cytomegalovirus Infections","enrollment":30},{"nctId":"NCT01329185","phase":"PHASE2","title":"Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2011-06","conditions":"EBV Viremia, CMV Viremia","enrollment":17},{"nctId":"NCT01335932","phase":"PHASE2","title":"Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-03-10","conditions":"Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure","enrollment":160},{"nctId":"NCT00294515","phase":"PHASE3","title":"IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03-31","conditions":"Cytomegalovirus Infections","enrollment":326},{"nctId":"NCT00466817","phase":"PHASE3","title":"Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-06","conditions":"Cytomegalovirus Infection","enrollment":109}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to VGCV","genericName":"Placebo to VGCV","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VGCV (valganciclovir) is a prodrug of ganciclovir that inhibits viral DNA polymerase to suppress cytomegalovirus (CMV) replication. Used for Cytomegalovirus (CMV) infection prophylaxis and treatment in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}